secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2023-05-19T23:59:59+00:00
Accession:  0001193125-23-149301
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Aeglea BioTherapeutics terminates CEO & GC; CFO Alspaugh appointed President
----------------------------------------------------------------------------

- President/CEO Jeffrey Goldberg and General Counsel Jim Kastenmayer terminated effective May 16, 2023.
- Additional severance: $50k to Goldberg, ~$34k to Kastenmayer; Kastenmayer retained as consultant for strategic alternatives.
- CFO Jonathan Alspaugh appointed President and principal executive officer.
- Retention bonus for Alspaugh up to $222,500 plus performance-based cash payment estimated ~$250k linked to strategic alternatives outcome.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000119312523149301/0001193125-23-149301-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000119312523149301/d458588d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-149301

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer